// App-Quantinova.ai

LB2365 : TIME-LIMITED VENETOCLAX-OBINUTUZUMAB +/- IBRUTINIB IS SUPERIOR TO CHEMOIMMUNOTHERAPY IN FRONTLINE CHRONIC LYMPHOCYTIC LEUKEMIA (CLL): PFS CO-PRIMARY ENDPOINT OF THE RANDOMIZED PHASE 3 GAIA/CLL13 TRIAL

Researchers

Presenter

  • Barbara Eichhorst

Principal Investigators

  • Arnon Kater

  • Moritz Frstenau

  • Julia von Tresckow

  • Can Zhang

  • Sandra Robrecht

  • Michael Gregor

  • Gunnar Juliusson

  • Patrick Thornton

  • Philipp Staber

  • Tamar Tadmor

  • Vesa Lindstrm

  • Caspar da Cunha-Bang

  • Christof Schneider

  • Christian B. Poulsen

  • Thomas Illmer

  • Bjrn Schttker

  • Ann Janssen

  • Ilse Christiansen

  • Thomas Nsslinger

  • Michael Baumann

  • Marjolein van der Klift

  • Ulrich Jger

  • Henrik Frederiksen

  • Maria Leys

  • Mels Hoogendoorn

  • Kourosh Lotfi

  • Holger Hebart

  • Tobias Gaska

  • Harry Koene

  • Florian Simon

  • Nisha De Silva

  • Anna Fink

  • Kirsten Fischer

  • Clemens Wendtner

  • Karl-Anton Kreuzer

  • Matthias Ritgen

  • Monika Brggemann

  • Eugen Tausch

  • Mark-David Levin

  • Marinus van Oers

  • Christian Geisler

  • Stephan Stilgenbauer

  • Michael Hallek

Medical Centers

  • Division of Hematology, Cantonal Hospital of Lucerne, Lucerne, Switzerland

  • Hepatology AKH, Medical University of Vienna, Vienna, Austria

  • Department of Advanced Home Care and Department of Clinical and Experimental Medicine, Linköping University, Linköping, USA

  • Medical University of Vienna, Vienna, Austria

  • Hanusch Hospital, Vienna, Austria

  • University College London Hospitals NHS Trust, London, United Kingdom

  • Department of Medicine I, Division of Hematology &amp

  • Clinic for Medical Oncology and Hematology,Cantonal Hospital St. Gallen,St. Gallen,Svizzera

  • Staufer Klinikum, Mutlangen, Mutlangen, Germany

  • Munich Clinic Schwabing, Academic Teaching Hospital, Ludwig-Maximilians-University, Munich, Germany

  • Department of Internal Medicine, Albert Schweitzer Hospital, Dordrecht, Netherlands

  • Beaumont/Cancer clinical trials Ireland,Dublin,Ireland

  • Health Psychology, University of Leuven, Leuven, Belgium

  • Department of Oncology, Odense University Hospital, Odense, Denmark

  • Clinic for Hematology and Stem Cell Transplantation, West German Cancer Center, University Hospital of Essen, University of Duisburg-Essen, Essen, Germany

  • Department of Oncology 5073 Rigshospitalet Copenhagen University Hospital, Copenhagen, Denmark

  • Department of Internal Medicine, University Hospital of Ulm, Ulm, Germany

  • Hematology und Oncology,Brüderkrankenhaus St. Josef,Paderborn,Germany

  • Rigshospitalet, Copenhagen, Denmark

  • Medical Center Leeuwarden, Leeuwarden, Netherlands

  • Department II of Internal Medicine, Campus Kiel, University of Schleswig-Holstein, Kiel, Germany

  • Hematology, Roskilde University Hospital, Roskilde, Denmark

  • Internal medicine, German CLL Study Group,University of Cologne,Cologne,Germany

  • Department of Internal Medicine,Amphia Hospital,Breda,Netherlands

  • Department of Pathology Lund University, Lund, Sweden

  • Hematology-Oncology Unit, Bnai Zion Medical Center, Haifa, Israel

  • Department 1 for Internal Medicine, Center for Integrated Oncology Koln-Bonn, University Hospital Cologne, Cologne, Germany

  • Department of Hematology, Helsinki University Hospital Comprehensive Cancer Center, University of Helsinki, Helsinki, Finland.

  • Department of Radiation Oncology, Academic Medical Center, Amsterdam, Netherlands

  • St Antonius Hospital, Nieuwegein, Netherlands

  • VU Amsterdam, Amsterdam, Netherlands

  • Department of Internal Medicine/Hematology,Maasstad Ziekenhuis,Rotterdam,Netherlands

  • Hämatologisch Onkologische Schwerpunktpraxis,Würzburg,Germany

  • BAG/Onkologische Schwerpunktpraxis,Dresden,Germany

  • Department of Oncology, Aalborg University Hospital, Aalborg, Denmark

Locations

  • Germany

  • Denmark

  • Netherlands

  • Switzerland

  • Sweden

  • Ireland

  • Austria

  • Israel

  • Finland

  • Belgium

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Chronic Lymphocytic Leukemia

Biomarkers

  • Creatinine

  • Girdin

  • Tumor protein p53

Drug/Treatment

  • Obinutuzumab

  • Obinutuzumab Intravenous

  • Venetoclax

  • Ibrutinib

  • Rituximab

  • TP53

Outcome

  • N/A

Study Design

  • Randomized

Phase

  • III

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved